Analysts Issue Forecasts for Genfit S.A.’s FY2026 Earnings (NASDAQ:GNFT)

Genfit S.A. (NASDAQ:GNFTFree Report) – Stock analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Genfit in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($0.67) per share for the year. The consensus estimate for Genfit’s current full-year earnings is ($0.23) per share. Leerink Partnrs also issued estimates for Genfit’s FY2027 earnings at ($0.14) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Genfit in a report on Friday, December 8th.

Check Out Our Latest Stock Report on Genfit

Genfit Trading Up 1.1 %

Shares of Genfit stock opened at $3.60 on Thursday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.95 and a current ratio of 2.95. The business has a 50 day moving average of $3.70 and a 200 day moving average of $3.49. Genfit has a 52 week low of $2.89 and a 52 week high of $4.75.

Hedge Funds Weigh In On Genfit

A number of institutional investors have recently added to or reduced their stakes in GNFT. BNP Paribas Arbitrage SNC raised its holdings in Genfit by 1,992.8% in the third quarter. BNP Paribas Arbitrage SNC now owns 11,845 shares of the company’s stock worth $43,000 after purchasing an additional 11,279 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Genfit by 561.4% during the first quarter. Envestnet Asset Management Inc. now owns 175,634 shares of the company’s stock valued at $50,000 after acquiring an additional 149,080 shares in the last quarter. O Shaughnessy Asset Management LLC increased its holdings in shares of Genfit by 29.6% during the first quarter. O Shaughnessy Asset Management LLC now owns 24,462 shares of the company’s stock valued at $99,000 after acquiring an additional 5,580 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Genfit by 181.8% during the third quarter. Citadel Advisors LLC now owns 35,319 shares of the company’s stock valued at $129,000 after acquiring an additional 22,786 shares in the last quarter. Finally, Optiver Holding B.V. increased its holdings in shares of Genfit by 1,005.2% during the second quarter. Optiver Holding B.V. now owns 296,612 shares of the company’s stock valued at $1,050,000 after acquiring an additional 269,775 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

Genfit Company Profile

(Get Free Report)

Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.

Read More

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.